A former CDC head on key R&D areas, public trust and if we learned anything from COVID-19

Dr. Julie Gerberding, now president and CEO of the Foundation for the National Institutes of Health, shares lessons learned from a long career in academic, public health and industry.

By Meagan Parrish • Dec. 13, 2023

Bristol Myers’ commercial chief on the industry’s ‘seismic’ changes over 27 years and what’s coming next

Adam Lenkowsky’s unique vantage point on the major transformations shaping BMS and the industry as a whole.

By Michael Gibney • Dec. 12, 2023

Explore the Trendline➔

Cell and gene therapies

How the industry is overcoming hurdles in cell and gene therapy space and pushing for the next generation of treatments.

By PharmaVoice staff

Oncology drugmakers seek the sweet spot between efficacy and tolerability

The FDA is now pushing companies to find the optimal dose early in development to minimize harm.

By Kelly Bilodeau • Dec. 11, 2023

The FDA just approved the first CRISPR drug. Here’s what’s next in gene editing.

A look at the fast-evolving pipeline for gene editing therapies.

By Meagan Parrish • Dec. 8, 2023

Real Chemistry’s CEO on biopharma’s outlook in 2024

Shankar Narayanan, CEO of marketing consulting firm Real Chemistry, weighs in on where the industry is headed in the New Year.

By Michael Gibney • Dec. 7, 2023

CRISPR eyes autoimmune disease in revamp of cell therapy plans

The gene editing biotech is shelving two of its most advanced cancer drugs, and joining a growing group of companies exploring cell-based medicines for inflammatory diseases like lupus.

By Ben Fidler • Dec. 6, 2023

BIO names longtime Amicus head John Crowley as new CEO

Crowley, a rare disease advocate who led Amicus for nearly two decades, will take the reins as the industry group seeks to challenge Medicare’s new drug pricing powers.

By Jonathan Gardner • Dec. 5, 2023

The weight loss market looks unstoppable. How high could it go?

Market expectations for obesity drugs are soaring and competition is heating up. But hitting the heights will require overcoming payer and other issues.

By Kelly Bilodeau • Dec. 4, 2023

The fortunes and flops of pharma M&A

Hindsight offers a better perspective on why some deals are fruitful and others fail.

By Alexandra Pecci • Dec. 4, 2023

How to succeed in biotech: A serial entrepreneur’s tips for surviving tough times

John Mulligan, founder of biotechs like Good Therapeutics and Bonum Therapeutics, discusses how biotechs can thrive when the market is against them.

By Michael Gibney • Nov. 30, 2023

Biopharma’s top 5 IPOs of 2023 (so far)

Despite one major outlier, 2023’s IPOs haven’t hit the heights of the past three years.

By Alexandra Pecci • Nov. 28, 2023

As alcohol-related deaths climb, new drugs could curb the urge to drink

A drug developed by Kinnov Therapeutics halved alcohol consumption in heavy drinkers in a mid-stage study.

By Kelly Bilodeau • Nov. 27, 2023

Biohaven wants to muscle in on the Ozempic craze with a competing class of drugs

Biohaven and other companies are aiming to develop meds with a different mechanism of action that trim the waistline while building lean tissue.

By Kelly Bilodeau • Nov. 20, 2023

​​A startling drop in U.S. life expectancy — and how pharma could help turn the tide

The recently observed dip was particularly acute for men, who now live an average of 5.8 fewer years than women.

By Meagan Parrish • Nov. 17, 2023

AstraZeneca showed the pandemic isn’t over for immunocompromised patients. What’s next?

Dr. Paul Moss, a hematology expert in the U.K., conducted a study with AstraZeneca showing the alarming extent to which immunocompromised patients are burdened with COVID-19.

By Michael Gibney • Nov. 16, 2023

The power of genomics-based healthcare remains largely untapped

23andMe co-founder and CEO Anne Wojcicki discusses ways the industry could integrate genomics into healthcare.

By Alexandra Pecci • Nov. 15, 2023

A biotech tackles drug discovery with transcription factor know-how

Talus Bio, which developed a platform to map transcription factors, has a lead cancer candidate in the works and consults with other industry players in the complicated biology.

By Michael Gibney • Nov. 15, 2023

Can Sarepta’s Duchenne gene therapy still deliver on its promise?

For Sarepta — and DMD patients — there’s a lot riding on the treatment’s next steps.

By Kelly Bilodeau • Nov. 14, 2023

Humans can’t shake the mosquito threat. Here’s what pharma has in the pipeline.

The arsenal against the world’s deadliest creature is growing and a universal vaccine is in the works.

By Kelly Bilodeau • Nov. 13, 2023

Optimizing KOL engagement and technology utilization in 2024

What if your advisory solution was a skillful blend of innovative tech, medical communications specialists, high-touch client service, and a flexible contract?

Nov. 13, 2023

5 of the best paid biopharma CEOs

As revenue growth remained high last year, so did biopharma CEO pay in the U.S.

By Alexandra Pecci • Nov. 10, 2023

Does BioMarin’s CEO shuffle signal bigger changes ahead?

With its long-time CEO on the way out, the rare disease biotech has seen an activist investor grow its stake.

By Meagan Parrish • Nov. 9, 2023

How pharma leaders talk about ethics in a highly criticized industry

The maze of ethical issues in biopharma can confound even the wiliest executive. How do some leaders get by?

By Michael Gibney • Nov. 9, 2023

What if a CRISPR cure isn’t such an easy choice?

A gene editing therapy developed by Vertex Pharmaceuticals and CRISPR Therapeutics can mute sickle cell disease’s most damaging symptoms. Yet treatment may not be as simple as its dramatic benefit makes it seem.

By Ned Pagliarulo , Shaun Lucas • Nov. 9, 2023

An at-home flu vaccine? If approved, it could open the door to more DIY options

A new way to administer vaccines at home could help AstraZeneca reach a wider market for FluMist, the nasal influenza vaccine.

By Kelly Bilodeau • Nov. 8, 2023